 | Up a level |
2022
Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2022). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017). Ann. Oncol., 33 (3). S. 355 - 356. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H. and Gluz, O. (2021). Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial. Ann. Oncol., 32. S. S1285 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2020
Christgen, M., Harbeck, N., Gluz, O., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Stefek, A., Krabisch, P., Just, M., Graeser, M., Baehner, R., Wuerstlein, R., Nitz, U., Kates, R. and Kreipe, H. (2020). High likelihood of actionable pDifferential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trialathogenic variant detection in breast cancer genes in women with very early onset breast cancer, but low rate of additional panel genes. Eur. J. Cancer, 138. S. S1 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R. and Kreipe, H. (2020). De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results. Ann. Oncol., 31. S. S1146 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2017
Gluz, O., Nitz, U., Christgen, M., Malter, W., Clemens, M., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Ppllmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Kuemmel, S., Liedtke, C., Shak, S., Kates, R., Wurstlein, R., Kreipe, H. H. and Harbeck, N. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. -M, Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann. Oncol., 28 (11). S. 2768 - 2773. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2016
Braun, M., Gluz, O., Nitz, U., Christgen, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., Kreipe, H. -H. and Harbecks, N. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. Oncol. Res. Treat., 39. S. 2 - 3. BASEL: KARGER. ISSN 2296-5262
Gluz, O., Nitz, U., Christgen, M., Kates, R., Clemens, M., Kraemer, S., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Lorenz-Salehi, F., Krabisch, P., Just, M., Augustin, D., Liedtke, C., Svedman, C., Shak, S., Wuerstlein, R., Kreipe, H. and Harbeck, N. (2016). Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. Eur. J. Cancer, 57. S. S6 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., de Haas, S. L., Kiermaier, A., Kreipe, H. H. and Nitz, U. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Liedtke, C., Gluz, O., Heinisch, F., Feuerhake, F., Kreipe, H. H., Clemens, M., Nuding, B., Kraemer, S., Reimer, T., Svedman, C., Shak, S., Nitz, U., Kates, R. E., Harbeck, N. and Christgen, M. (2016). Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) A translational analysis of the prospective WSG planB trial. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
2015
Gluz, O., Nitz, U., Kreipe, H. H., Christgen, M., Kates, R. E., Hofmann, D., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., Kusche, M., Heyl, V., Lorenz-Salehi, F., Just, M., Liedtke, C., Wuerstlein, R. and Harbeck, N. (2015). Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX (R): First prospective survival results from the WSG phase III planB trial. Eur. J. Cancer, 51. S. S311 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Nitz, U., Gluz, O., Kreipe, H., Christgen, M., Kates, R. E., Clemenss, M., Kraemer, S., Aktas, B., Kuemmel, S. and Harbeck, N. (2015). Risk assessment by St.Gallen 2013 recommendation and Oncotype DX (R): results from the WSG PlanB trial. Breast, 24. S. S110 - 1. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080
Nitz, U., Gluz, O., Kreipe, H., Christgen, M., Kates, R. E., Clemenss, M., Kraemer, S., Aktas, B., Kuemmel, S. and Harbeck, N. (2015). Risk assessment by St.Gallen 2013 recommendation and Oncotype DX (R): results from the WSG PlanB trial. Breast, 24. S. S110 - 1. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080
2013
Harbeck, N., Gluz, O., Kreipe, H. H., Christgen, M., Svedman, C., Shak, S., Hofmann, D., Kuemmel, S., Nuding, B., Rezai, M., Schumacher, C., Kusche, M., Forstbauer, H., Maass, N., Kraemer, S., Aktas, B., Mohrmann, S., Wuerstlein, R., Kates, R. E. and Nitz, U. (2013). Run-in phase of prospective WSG-ADAPT HR+/ HER2-trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
2012
Gluz, O., Kreipe, H. H., Kates, R. E., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Salem, M., Liedtke, B., Aktas, B., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2012). Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
2011
Giuz, O., Kreipe, H., Degenhardt, T., Kates, R., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2011). Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
2010
Gluz, O., Kreipe, H., Christgen, M., Salem, M., Clemens, M., Markmann, S., Liedtke, B., Barinoff, J., Aktas, B., Henschen, S., Luebbe, K., Shak, S., Baehner, R., Liedtke, C., Nitz, U. and Harbeck, N. (2010). Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX (R) and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445